Borealis
QuietHanover, NHHealthcare, Biotechnology, PharmaceuticalsLast fund filed May 2022
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Borealis Fund VI, LP | May 2022 | $100M | $5.3M | 16 |
| Borealis Fund V - Veterinary Innovation, LP | October 2021 | $50M | $34M | 55 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
4 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Benjamin Shaw | Quiet | Enterprise software, Digital health, Food & agriculture | 4 |
Classified sectors of Borealis’s own portfolio companies, based on 11 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Caduceus Capital | 3 | AVEDRO, Compass Therapeutics, Compass Therapeutics |
| Orbimed Asia Partners | 3 | AVEDRO, Compass Therapeutics, Compass Therapeutics |
| Orbimed Genesis | 3 | AVEDRO, Compass Therapeutics, Compass Therapeutics |
| Orbimed Global Healthcare |
| 0 |
| Emily Snyder | Quiet | Digital health | 1 | 0 |
| Julia StephanusNot on the current fund | Quiet | None listed | 0 | 0 |
| Philip Ferneau | Quiet | Biotech & pharma, Enterprise software, Medical devices | 8 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Borealis’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 3 |
| AVEDRO, Compass Therapeutics, Compass Therapeutics |
| Orbimed Israel Partners | 3 | AVEDRO, Compass Therapeutics, Compass Therapeutics |
| Orbimed New Horizons | 3 | AVEDRO, Compass Therapeutics, Compass Therapeutics |
| Orbimed Partners | 3 | AVEDRO, Compass Therapeutics, Compass Therapeutics |
| Orbimed Private Investments | 3 | AVEDRO, Compass Therapeutics, Compass Therapeutics |
| Polaris Partners | 3 | Amagma, Ankyra Therapeutics, Blue Rabbit Ventures |
| 270 Healthcare Growth | 2 | Compass Therapeutics, Compass Therapeutics |
| 82vs | 2 | Avitide, Compass Therapeutics |
| Atlas Venture | 2 | Amagma, Direct Vet Marketing |
| Green D Founders Fund 2014-i Lllp | 2 | Avitide, Compass Therapeutics |
| GTP AW | 2 | Avitide, Compass Therapeutics |
| Abingworth Bioventures | 1 | AVEDRO |
A shared board seat: a company where filings name a Borealis partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.